Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis

Jason F. Huntley, Patrick G. Conley, David A. Rasko, Kayla E. Hagman, Michael A. Apicella, Michael V. Norgard

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Francisella tularensis is a gram-negative intracellular bacterium and the causative agent of the zoonotic disease tularemia. F. tularensis is a category A select agent and thus a potential agent of bioterrorism. Whereas an F. tuforensis live, attenuated vaccine strain (LVS) is the basis of an investigational vaccine, this vaccine is not licensed for human use because of efficacy and safety concerns. In the present study, we immunized mice with isolated native outer membrane proteins (OMPs), ethanol-inactivated LVS (iLVS), or purified LVS lipopolysaccharide (LPS) and assessed the ability of each vaccine preparation to protect mice against pulmonary challenge with the virulent type A F. tularensis strain SchuS4. Antibody isotyping indicated that both Th1 and Th2 antibody responses were generated in mice after immunization with OMPs or iLVS, whereas LPS immunization resulted in only immunoglobulin A production. In survival studies, OMP immunization provided the greatest level of protection (50% survival at 20 days after infection with SchuS4), and there were associated 3-log reductions in the spleen and liver bacterial burdens (compared to nonvaccinated mice). Cytokine quantitation for the sera of SchuS4-challenged mice indicated that OMP and iLVS immunizations induced high levels of tumor necrosis factor alpha and interleukin-2 (IL-2) production, whereas only OMP immunization induced high levels of IL-10 production. By comparison, high levels of proinflammatory cytokines, including RANTES, granulocyte colony-stimulating factor, IL-6, IL-1α, IL-12p40, and KC, in nonvaccinated mice indicated that these cytokines may facilitate disease progression. Taken together, the results of this study demonstrate the potential utility of an OMP subunit (acellular) vaccine for protecting mammals against type A F. tularensis.

Original languageEnglish (US)
Pages (from-to)3664-3671
Number of pages8
JournalInfection and Immunity
Volume76
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Francisella tularensis
Membrane Proteins
Immunization
Lung
Attenuated Vaccines
Vaccines
Cytokines
Lipopolysaccharides
Biological Warfare Agents
Acellular Vaccines
Interleukin-12 Subunit p40
Tularemia
Chemokine CCL5
Subunit Vaccines
Survival
Protein Subunits
Zoonoses
Granulocyte Colony-Stimulating Factor
Gram-Negative Bacteria
Interleukin-1

ASJC Scopus subject areas

  • Immunology

Cite this

Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. / Huntley, Jason F.; Conley, Patrick G.; Rasko, David A.; Hagman, Kayla E.; Apicella, Michael A.; Norgard, Michael V.

In: Infection and Immunity, Vol. 76, No. 8, 08.2008, p. 3664-3671.

Research output: Contribution to journalArticle

Huntley, Jason F. ; Conley, Patrick G. ; Rasko, David A. ; Hagman, Kayla E. ; Apicella, Michael A. ; Norgard, Michael V. / Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. In: Infection and Immunity. 2008 ; Vol. 76, No. 8. pp. 3664-3671.
@article{0c2da05609984a7589b3587a5e7d4d30,
title = "Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis",
abstract = "Francisella tularensis is a gram-negative intracellular bacterium and the causative agent of the zoonotic disease tularemia. F. tularensis is a category A select agent and thus a potential agent of bioterrorism. Whereas an F. tuforensis live, attenuated vaccine strain (LVS) is the basis of an investigational vaccine, this vaccine is not licensed for human use because of efficacy and safety concerns. In the present study, we immunized mice with isolated native outer membrane proteins (OMPs), ethanol-inactivated LVS (iLVS), or purified LVS lipopolysaccharide (LPS) and assessed the ability of each vaccine preparation to protect mice against pulmonary challenge with the virulent type A F. tularensis strain SchuS4. Antibody isotyping indicated that both Th1 and Th2 antibody responses were generated in mice after immunization with OMPs or iLVS, whereas LPS immunization resulted in only immunoglobulin A production. In survival studies, OMP immunization provided the greatest level of protection (50{\%} survival at 20 days after infection with SchuS4), and there were associated 3-log reductions in the spleen and liver bacterial burdens (compared to nonvaccinated mice). Cytokine quantitation for the sera of SchuS4-challenged mice indicated that OMP and iLVS immunizations induced high levels of tumor necrosis factor alpha and interleukin-2 (IL-2) production, whereas only OMP immunization induced high levels of IL-10 production. By comparison, high levels of proinflammatory cytokines, including RANTES, granulocyte colony-stimulating factor, IL-6, IL-1α, IL-12p40, and KC, in nonvaccinated mice indicated that these cytokines may facilitate disease progression. Taken together, the results of this study demonstrate the potential utility of an OMP subunit (acellular) vaccine for protecting mammals against type A F. tularensis.",
author = "Huntley, {Jason F.} and Conley, {Patrick G.} and Rasko, {David A.} and Hagman, {Kayla E.} and Apicella, {Michael A.} and Norgard, {Michael V.}",
year = "2008",
month = "8",
doi = "10.1128/IAI.00374-08",
language = "English (US)",
volume = "76",
pages = "3664--3671",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis

AU - Huntley, Jason F.

AU - Conley, Patrick G.

AU - Rasko, David A.

AU - Hagman, Kayla E.

AU - Apicella, Michael A.

AU - Norgard, Michael V.

PY - 2008/8

Y1 - 2008/8

N2 - Francisella tularensis is a gram-negative intracellular bacterium and the causative agent of the zoonotic disease tularemia. F. tularensis is a category A select agent and thus a potential agent of bioterrorism. Whereas an F. tuforensis live, attenuated vaccine strain (LVS) is the basis of an investigational vaccine, this vaccine is not licensed for human use because of efficacy and safety concerns. In the present study, we immunized mice with isolated native outer membrane proteins (OMPs), ethanol-inactivated LVS (iLVS), or purified LVS lipopolysaccharide (LPS) and assessed the ability of each vaccine preparation to protect mice against pulmonary challenge with the virulent type A F. tularensis strain SchuS4. Antibody isotyping indicated that both Th1 and Th2 antibody responses were generated in mice after immunization with OMPs or iLVS, whereas LPS immunization resulted in only immunoglobulin A production. In survival studies, OMP immunization provided the greatest level of protection (50% survival at 20 days after infection with SchuS4), and there were associated 3-log reductions in the spleen and liver bacterial burdens (compared to nonvaccinated mice). Cytokine quantitation for the sera of SchuS4-challenged mice indicated that OMP and iLVS immunizations induced high levels of tumor necrosis factor alpha and interleukin-2 (IL-2) production, whereas only OMP immunization induced high levels of IL-10 production. By comparison, high levels of proinflammatory cytokines, including RANTES, granulocyte colony-stimulating factor, IL-6, IL-1α, IL-12p40, and KC, in nonvaccinated mice indicated that these cytokines may facilitate disease progression. Taken together, the results of this study demonstrate the potential utility of an OMP subunit (acellular) vaccine for protecting mammals against type A F. tularensis.

AB - Francisella tularensis is a gram-negative intracellular bacterium and the causative agent of the zoonotic disease tularemia. F. tularensis is a category A select agent and thus a potential agent of bioterrorism. Whereas an F. tuforensis live, attenuated vaccine strain (LVS) is the basis of an investigational vaccine, this vaccine is not licensed for human use because of efficacy and safety concerns. In the present study, we immunized mice with isolated native outer membrane proteins (OMPs), ethanol-inactivated LVS (iLVS), or purified LVS lipopolysaccharide (LPS) and assessed the ability of each vaccine preparation to protect mice against pulmonary challenge with the virulent type A F. tularensis strain SchuS4. Antibody isotyping indicated that both Th1 and Th2 antibody responses were generated in mice after immunization with OMPs or iLVS, whereas LPS immunization resulted in only immunoglobulin A production. In survival studies, OMP immunization provided the greatest level of protection (50% survival at 20 days after infection with SchuS4), and there were associated 3-log reductions in the spleen and liver bacterial burdens (compared to nonvaccinated mice). Cytokine quantitation for the sera of SchuS4-challenged mice indicated that OMP and iLVS immunizations induced high levels of tumor necrosis factor alpha and interleukin-2 (IL-2) production, whereas only OMP immunization induced high levels of IL-10 production. By comparison, high levels of proinflammatory cytokines, including RANTES, granulocyte colony-stimulating factor, IL-6, IL-1α, IL-12p40, and KC, in nonvaccinated mice indicated that these cytokines may facilitate disease progression. Taken together, the results of this study demonstrate the potential utility of an OMP subunit (acellular) vaccine for protecting mammals against type A F. tularensis.

UR - http://www.scopus.com/inward/record.url?scp=48849092218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849092218&partnerID=8YFLogxK

U2 - 10.1128/IAI.00374-08

DO - 10.1128/IAI.00374-08

M3 - Article

VL - 76

SP - 3664

EP - 3671

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 8

ER -